Takeda Pharmaceutical Co., Ltd.

Takeda Pharmaceutical Co., Ltd. saw a significant rise in stock price on April 1, 2026, amid a mixed market environment. Year-to-date, the company has outperformed the Nikkei index, although its annual performance lags behind. Challenges include low ROCE and a high Debt to Equity ratio, despite healthy long-term growth in net sales.

Takeda Pharmaceutical Co., Ltd. saw a significant stock decline amid a broader market downturn, with its shares dropping to an intraday low. Despite recent weekly and monthly losses, the company has shown strong annual growth in net sales and operating profit, although it faces challenges in financial metrics.

Takeda Pharmaceutical Co., Ltd. saw its stock decline significantly today, contrasting with the Japan Nikkei 225's modest decrease. Over the past month, Takeda's performance has lagged behind the index, with financial metrics indicating challenges such as low returns and a high debt-to-equity ratio amid a drop in net profit.